Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812316 | 0.91 | CCR3 (0.40) | DRD4CCR3DRD3CNR2PPARG | |
| Hydrochloric Acid SCHEMBL1809459 | 0.90 | CCR3 (0.39) | DRD4CCR3EPHA2KDREPHB4 | |
| Hydrochloric Acid SCHEMBL1807020 | 0.85 | GRN (0.44) | DRD4CCR3CNR2 | |
| SCHEMBL1811965 | 0.85 | ALDH1A1 (0.48) | DRD4CCR3DRD3ALDH1A1SIGMAR1 | |
| SCHEMBL1811962 | 0.85 | ALDH1A1 (0.48) | DRD4CCR3DRD3ALDH1A1SIGMAR1 | |
| SCHEMBL1810235 | 0.84 | DRD4 (0.44) | DRD4CCR3CNR2SIGMAR1 | |
| SCHEMBL1812698 | 0.84 | CCR3 (0.41) | DRD4CCR3DRD3CNR2SIGMAR1 | |
| SCHEMBL1813440 | 0.83 | CCR3 (0.42) | DRD4CCR3DRD2DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1809318 | 0.83 | CCR3 (0.42) | DRD4CCR3DRD3CNR2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1808736 | 0.83 | CCR3 (0.40) | DRD4CCR3EPHA2KDRDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | DRD4 768/4885CCR3 1/4885CTSK 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.